GlobalData on MSN4d
Kezar Life Sciences discontinues lupus nephritis programme after fatalities
Clinical stage biopharma Kezar Life Sciences is discontinuing its lupus nephritis (LN) clinical programme following the death ...
Medscape39m
Therapeutic Drug Monitoring in Rheumatology Has Potential but Faces a Host of Hurdles
Tracking patient response to DMARD therapy has the potential to improve remission, but multiple barriers must be overcome ...
BioWorld13d
Sex-specific model of lupus-like cardiovascular disease
Clinical research has shown that patients with systemic lupus erythematosus (SLE) are more likely to develop cardiovascular ...
BioSpace5d
Kezar Cuts Lupus Program After Patient Deaths, Focuses on Autoimmune Hepatitis
Earlier this month, Kezar Life Sciences announced that the mid-stage test of zetomipzomib in lupus nephritis had been placed ...
Pharmabiz6d
Cullinan Therapeutics gets US FDA clearance to proceed phase 1 trial of CLN-978 in patients with moderate to severe systemic lupus erythematosus
Cambridge, Massachusetts Thursday, October 17, 2024, 17:00 Hrs [IST] ...
The Lupus Research Alliance Walk with Us to Cure Lupus Raises Millions for Lupus Research
Thousands of passionate people with lupus and those who care about the cause will join together Saturday, October 19 at the ...
studyfinds13d
Cell revival in a coffee cup? Caffeine’s surprising effect on lupus patients’ blood vessels
A new study suggests that your morning cup of coffee might do more than just wake you up – it could be giving your blood ...
Climb Bio to Provide Budoprutug Development Strategy and Corporate Update at Virtual Investor Event
Completes Transition to Immune-Mediated Disease Focused CompanyHighlights Additional Data from Phase 1b Primary Membranous ...
Kezar to terminate mid-stage trial for Lupus treatment
The regulator's decision came after the company paused the study in September to review safety data following the deaths of ...
The Free Press Journal52m
Metropolis Study Reveals 30% Increase In ANA Positivity In Indian Population Post-COVID, Indicating Rising Autoimmune Disease Risk
The research has been published in the International Journal of Clinical Biochemistry and Research ... Conditions such as ...
Kezar discontinues development of zetomipzomib for lupus nephritis
Kezar (KZR) is discontinuing development of its drug zetomipzomib for the treatment of lupus nephritis so it can focus on ...
Investing7d
FDA approves Cullinan's lupus drug for Phase 1 trials
to proceed with Phase 1 clinical trials in the United States for its drug candidate CLN-978, targeting systemic lupus erythematosus (SLE), a chronic autoimmune disease. The clearance allows the ...